Biotech Co.* (Symbol) |
Pharma Co. (Symbol/Country) |
Type/Product Area |
Disclosed Funding (M) |
Terms/Details (Date) |
3-Dimensional Pharmaceuticals Inc.* |
DuPont Pharmaceuticals Co. (subsidiary of E.I. DuPont de Nemours & Co.; NYSE:DD) |
Research collaboration/target discovery and use of 3-D's Directed Diversity technology to generate combinatorial chemistry libraries for drug discovery |
$9 |
3-D will generate custom libraries and optimize them to obtain preclinical candidates; for the initial target, 3-D will receive up to $9M, including an up-front technology access fee, R&D funding and milestones; 3-D also will receive royalties on any sales and will be eligible to receive additional payments if more than one target is selected; additional agreement provides DuPont a non-exclusive license to Directed Diversity to support internal projects; DuPont will pay an annual site license fee for each facility using the technology (2/00) |
Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim International GmbH; Germany) |
Research collaboration/use of 3-D's Directed-Diversity combinatorial chemistry to discover and refine compounds active against BI targets |
ND |
3-D will receive an up-front technology access fee, R&D funding, milestones and royalties on each target selected; BI is responsible for preclinical and clinical development (3/00) |
|
Alkermes Inc. (ALKS) |
Ares-Serono |
Research collaboration/development of extended-release version of an undisclosed AresSerono therapeutic protein |
$30 |
Ares-Serono gains exclusive worldwide rights to products resulting from the collaboration, and will provide development funding, milestones that could exceed $30M, plus royalties based on sales; Alkermes is expected to manufacture products; Ares-Serono will handle clinical trials, approvals and marketing (1/00) |
Glaxo Wellcome plc (UK; NYSE: GLX) |
License agreement and research and development collaboration/use of Alkermes' AIR pulmonary drug delivery technology for multiple product candidates in respiratory diseases |
ND |
Glaxo receives exclusive worldwide rights to products in up to four undisclosed respiratory disease categories, and will provide development funding and milestones, as well as royalties on product sales; each company will have manufacturing rights and obligations; Glaxo is responsible for clinical trials, regulatory approvals and marketing (2/00) |
|
Alkermes Inc. (ALKS) |
Eli Lilly and Co. (NYSE:LLY) |
License agreement and research and development collaboration/inhaled formulation of human growth hormone based on Alkermes' AIR pulmonary drug delivery system |
ND |
Agreement follows succesful completion of nine-month feasibility program conducted by the two companies; Alkermes will receive up-front fees, research funding and milestones, plus royalties on any sales; Lilly receives exclusive worldwide rights and will be responsible for clinical trials, regulatory approvals and marketing on a worldwide basis (2/00) |
American Biogenetic Sciences Inc. (OTC BB:MABA) |
Abbott Laboratories (NYSE:ABT) |
License agreement/ABS' neurological compound ABS-103 (derivative of epilepsy drug valproate) |
ND |
Abbott gains exclusive worldwide rights to develop and market the compound, and will make an up-front equity investment as well as additional milestone payments (1/00) |
AMRAD (Australia) |
Ares-Serono Group (Switzerland) |
License agreement and research collaboration/recombinant leukemia inhibitory factor for use in the field of reproductive health |
$16 |
Ares-Serono made an undisclosed up-front payment and will pay milestones of up to $16M, plus royalties on any product sales; AMRAD is developing the protein for neuromuscular diseases under the name AM424 (1/00) |
Arena Pharmaceuticals Inc.* |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
Research collaboration/validation of orphan G protein-coupled receptors as drug screening targets; use of Arena's CART technology to identify modulators of GPCRs in a ligand independent manner |
ND |
Companies will jointly validate selected GPCR targets; Arena will be responsible for receptor identification and regulation, application of its CART technology to Fujisawa-selected receptors and validation of screening assays based upon selected receptors; Fujisawa will screen its compound library using CART receptor assays and will handle preclinical and clinical development of leads; agreement includes an opportunity for Arena to screen selected receptors using its in-house library; Arena will receive assay license, milestone and potential royalty payments (1/00) |
Argonex Inc.* |
Wyeth-Lederle Vaccines (division of American Home Products Corp.; NYSE: AHP) |
Research collaboration/identification of antigens associated with Chlamydia pneumoniae for development of potential vaccines |
ND |
Argonex will use its antigen technology to isolate, identify and sequence peptides uniquely expressed on cells infected with C. pneunomiae; Wyeth-Lederle will evaluate the peptides for potential use in vaccine development; Argonex will receive research funding and potential royalties (2/00) |
Array BioPharma Inc.* |
Asahi Chemical Industry Co. Ltd. |
Research collaboration/access to Array's small-molecule libraries |
ND |
Asahi gains access to Array's libraries on a semi-exclusive basis (3/00) |
Artemis Pharmaceuticals GmbH* (Germany) |
Bayer AG (Germany) |
Research collaboration/use of Artemis technology to develop methods for toxicology testing for pharmaceutical and crop protection compounds |
ND |
ND (2/00) |
Axys Advanced Technologies Inc. (subsidiary of Axys Pharmaceuticals Inc.; AXPH) |
Genomics Institute of the Novartis Research Foundation (unit of Novartis AG;Switzerland) |
Research collaboration/use of small-molecule compounds created using Axys' combinatorial chemistry technologies |
ND |
The institute will screen the compounds to detect changes in gene expression; in addition the entities will develop novel chemistries together (1/00) |
Bristol-Myers Squibb Co. (NYSE:BMY) |
Research collaboration/use of Axys compounds for screening, plus transfer of technologies for reproducing and expanding the library |
ND |
Axys will receive payments for product delivery and technology transfer (2/00) |
|
Avigen Inc. (AVGN) |
BTG International Inc. (subsidiary of BTG plc; LSE: BGC) |
License agreement/gene therapy using Factor IX for treatment of hemophilia B |
ND |
Avigen licensed rights to Factor IX for use in its gene therapy delivery system; Avigen will pay an up-front fee and milestones (3/00) |
BioFocus plc* (UK) |
Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim; Germany) |
Research collaboration/compound design and synthesis, plus analysis of resulting biological screening data |
ND |
BioFocus will provide chemistry support and analysis of screening data (2/00) |
Bioject Medical Technologies Inc. (BJCT) |
Serono Laboratories Inc. (U.S. affiliate of the Ares-Serono Group; Switzerland) |
License agreement/development of customized version of Bioject's needle-free delivery system to deliver Serono's Saizan recombinant human growth hormone |
ND |
Serono has U.S. and Canadian rights to use the system for its growth hormone, and will pay an undisclosed license fee; the companies signed a supply agreement that commences upon FDA clearance (1/00) |
Bioreason Inc.* |
Pharmacia & Upjohn (NYSE: PNU) |
Evaluation agreement/use of Bioreason's suite of process improvements for screening |
ND |
P&U will evaluate the impact of Bioreason's technology and services on lead discovery and characterization (2/00) |
Coley Pharmaceutical Group (formerly CpG ImmunoPharmaceuticals) |
SmithKline Beecham (NYSE:SBH) |
License agreement/development of immunotherapeutic products based on CpG DNA, including lead immune stimulant CpG 7909 |
$72 |
SmithKline gains a worldwide coexclusive license to CpG DNA-based compounds for use in certain therapeutic and prophylactic vaccines for infectious diseases; in exchange, Coley could receive up to $72M in license fees, research funding and milestones, including an $8M up-front payment (1/00) |
CytRx Corp. (CYTR) |
ND |
Evaluation agreement/use of CytRx's gene delivery technology in a gene-based vaccine for HIV |
ND |
A "major pharmaceutical company" is evaluating the CytRx technology, and has an exclusive option to license the technology under terms to be negotiated; CytRx will provide material and consulting services during the evaluation period in exchange for certain payments (3/00) |
Deltagen Inc.* |
Merck & Co. Inc. (NYSE:MRK) |
Research collaboration/production and analysis of knockout mice in order to characterize gene function |
ND |
Merck will provide target gene sequences, and Deltagen will produce and analyze knockout mice (2/00) |
Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP) |
Research collaboration/validation of small-molecule drug targets using knockout mice, which aid in characterizing gene function |
ND |
Schering-Plough will provide target gene sequences, and Deltagen will produce and analyze knockout mice (2/00) |
|
DGI BioTechnologies LLC* |
Novo Nordisk A/S (Denmark; NYSE:NVO) |
Expansion of 6/99 collaboration using DGI's Diogenesis drug lead discovery platform |
ND |
Updated agreement provides supplemental funding to support accelerated pace of research (3/00) |
DoubleTwist Inc.* |
Berlex Laboratories Inc. (unit of Schering AG; Germany) |
License agreement/DoubleTwist's clustering and alignment tools for genomic data |
ND |
Berlex gains a non-exclusive license (2/00) |
D-Pharm Ltd.* (Israel) |
Shire Pharmaceuticals Group plc (LSE:SHP) |
License agreement/D-Pharma's DP-VPA, a chemical analogue of valproic acid for the treatment of central nervous system disorders |
ND |
D-Pharm receives an up-front fee and equity investment, as well as milestones; D-Pharm retains manufacturing rights and intends to become sole supplier of bulk compound, which Shire will purchase at a price that includes a royalty rate; Shire will be responsible for development and regulatory activities (3/00) |
Dynavax Technologies Corp.* |
Aventis Pasteur (unit of Aventis SA; NYSE:AVE) |
Research collaboration/development of new prophylactic and therapeutic vaccines for the diseases using Dynavax's immunostimulatory DNA sequences treatment of infectious |
ND |
Aventis Pasteur has the option to acquire exclusive worldwide rights to use ISS for specific disease targets in return for equity investments, research and development funding, milestones and royalties; Genavent, a venture capital fund of Societe Generale Asset Management and Aventis, will make an equity investment (2/00) |
Elan Corp. plc (NYSE:ELN) |
Wyeth-Ayerst Research (unit of American Home Products Corp.; NYSE:AHP) |
Research, development and license agreement/small-molecule inhibitors of Elan's cell-adhesion molecule Alpha4-Beta2 |
ND |
Companies collaborated in the integrin inhibitor field from 1991-97; under new agreement, Elan received an up-front payment and could receive additional fees and milestones, plus royalties; Elan may opt to co-promote products with Wyeth for a share of operating profits in lieu of royalty (1/00) |
Electrofect* |
Boehringer Ingelheim GmbH International (Germany) |
License agreement/Electrofect's electroporation technology for DNA delivery in the field of oncology |
ND |
Non-exclusive license; further details ND (2/00) |
Endorex Corp. (AMEX:DOR) and Elan Corp. plc (NYSE:ELN) |
Schein Pharmaceutical Inc. (NYSE:SHP) |
License, co-development and supply agreement/iron chelating products using Elan's Medipad drug delivery system for treatment of certain genetic blood disorders resulting from iron overload |
ND |
Schein receives an exclusive worldwide sublicense to utilize Medipad for delivery of a Schein iron chelator; in the U.S., the groups will develop a drug/device product as part of a clinical testing program; Schein has U.S. marketing products and the companies together will identify sublicensees for international markets (2/00) |
Endorex Corp. (AMEX:DOR) |
Novo Nordisk A/S (Denmark; NYSE:NVO) |
Research and option agreement/formulation >of Novo's Norditropin brand of human growth hormone using Endorex's Orasome oral delivery system |
ND |
Novo has exclusive worldwide rights to license the Orasome system for Norditropin; companies will further evaluate product in animal models (3/00) |
EpiGenesis Pharmaceuticals Inc.* |
Chisei Faramaceutici SpA (Italy) |
License and development agreement/EpiGenesis' EPI-2010, an antisense oligonucleotide for treatment of respiratory diseases |
ND |
EpiGenesis will receive development payments, as well as milestone fees and royalties on sales; Chisei will receive semi-exclusive marketing rights for the product and its use in asthma for Europe and other countries where Chisei has a presence; agreement includes possibility of a future collaboration for additional indications (1/00) |
Gene Logic Inc. (GLGC) |
Pfizer Inc. (NYSE:PFE) |
Database subscription/access to Gene Logic's GeneExpress database of gene expression information for predictive toxicology applications |
ND |
Pfizer gains access to the database and will pay annual subscription fees (2/00) |
Genset SA (France; GENXY) |
Abbott Laboratories (NYSE:ABT) |
Research collaboration/discovery of genes associated with bipolar disorder and Type II diabetes |
ND |
Abbott will receive a license to develop and commercialize therapeutic and diagnostic products based on genes identified through the collaboration; Genset will receive an up-front payment, research funding, milestones and royalties; Genset may exercise a put option to issue $10M worth of equity to Abbott (3/00) |
Idun Pharmaceuticals* |
Becton, Dickinson and Co. (NYSE: BDX) |
License agreement/apoptosis reagents for use in the research market |
ND |
BD is exclusive licensee of Idun's apoptosis research reagents, and has the right to grant sublicenses; Idun receives an up-front payment, as well as royalties on sales (1/00) |
IGI Inc. (AMEX:IG) |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
Development agreement/use of IGI's Novasome microencapsulation technology to develop a topical delivery system for a Fujisawa dermatological compound |
ND |
IGI will develop new formulation of undisclosed compound and will receive an up-front technology payment and potential milestones (1/00) |
ImClone Systems Inc. (IMCL) |
SmithKline Beecham plc (NYSE:SBH) |
License agreement/proprietary antigens and related intellectual property owned by ImClone for inclusion in a vaccine against meningitis |
ND |
ImClone will receive an up-front fee and payments upon the achievement by SmithKline of certain clinical and regulatory milestones, plus royalties on sales (2/00) |
Insmed Pharmaceuticals Inc.* |
Taisho Pharmaceutical Co. Ltd. (Japan) |
Letter of intent for development and commercialization rights/INS-1, a low-molecular-weight oral drug for polycystic ovary syndrome and Type II diabetes |
ND |
Taisho signed a letter of intent for rights to Insmed's INS-1 in Japan and other Asian countries; Taisho will pay up-front, development, milestone and royalty payments pursuant to a definitive agreement to be negotiated; in addition, Taisho will invest several million dollars in Insmed equity (3/00) |
Isis Pharmaceuticals (ISIP) |
AstraZeneca plc (UK; NYSE:AZN) |
Research collaboration/use of Isis' antisense technology to assess and prioritize genes identified within Astra-Zeneca's genomics programs |
ND |
Isis will create antisense inhibitors to target genes in order to gather functional information (1/00) |
Lexicon Genetics Inc.* |
Roche Bioscience (unit of Roche Holding Ltd.; Switzerland) |
Sublicense agreement/use of certain aspects of Lexicon's positive-negative selection and isogenic DNA technology to improve efficiency of genes targeted in knockout mice |
ND |
Roche will use the technology for its internal programs (1/00) |
Lexicon Genetics Inc.* |
R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; (NYSE:JNJ) |
Research collaboration/access to Lexicon's knockout mouse technology, and to its Seek Target Validation program to determine the function and pharmaceutical relevance of genes by analyzing knockout mice |
ND |
Multi-year agreement; details ND (1/00) |
Searle (pharmaceutical division of Monsanto Co.; NYSE:MTC) |
Research collaboration/access to Lexicon's knockout mouse technology |
ND |
Multi-year agreement under whichSearle will pay annual access and project fees with minimum annual commitments (1/00) |
|
Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim GmbH International; Germany) |
Research collaboration/Internet access to Lexicon's gene sequence database and library of knockout mouse clones for use in determining the function of genes that represent potential gene targets |
ND |
Multi-year agreement under which BI will have non-exclusive access to Lexicon's OmniBank database in exchange for annual access fees; Lexicon also may receive royalties on sales of products developed using genes discovered using the database; BI also will have access to knockout mice in exchange for agreed-upon fees with minimum annual commitments (2/00) |
|
Lexicon Genetics Inc.* |
NV Organon (the Netherlands) |
Research collaboration/access to Lexicon's knockout mouse technology |
ND |
Multi-year agreement under which Organon will pay annual access and project fees with minimum annual commitments (2/00) |
LifeSpan BioSciences Inc.* |
Pfizer Inc. (NYSE:PFE) |
Database subscription/database of information on the expression and localization of G protein-coupled receptors |
ND |
Pfizer receives early access to localization data on GPCR targets, which will be added continuously to the database over a two-year period (3/00) |
Life Technologies Inc. (OTC BB:LTEK) |
Amgen Inc. (AMGN) |
Research collaboration/use of Life's full-length cDNA library technology to complement Amgen's gene discovery efforts |
ND |
Terms call for a payment for each full-length cDNA library constructed, as well as payments for each full-length clone selected by Amgen for discovery research (2/00) |
Ligand Pharmaceuticals Inc. (LGND) |
NV Organon (The Netherlands) |
Research collaboration/discovery and development of small-molecule compounds for treating and preventing gynecological diseases mediated through the progesterone receptor |
ND |
Ligand received undisclosed up-front payments for research reimbursements and may receive milestones and royalties; Organon gains exclusive worldwide rights to manufacture and sell any resulting products (2/00) |
Inpharmatica* (UK) |
Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA) |
Bioinformatics access/Inpharmatica's Biopendium platform for identifying, prioritizing and validating drug targets |
ND |
Parke-Davis signed a three-year, multimillion dollar agreement to become the first partner to gain access to Biopendium; Parke-Davis has an option to expand and extend the collaboration (1/00) |
Medarex Inc. (MEDX) |
Kirin Brewery Co. Ltd. (Japan) |
Cross-licensing agreement and research collaboration/mouse technology for creating monoclonal antibodies (Medarex's HuMAb Mouse and Kirin's Transchromosomic Mouse) |
$12M |
Kirin will pay a $12M up-front fee for exclusive rights to distribute the technology in Asia; Medarex gains exclusive distrbution rights to Kirin's mouse technology outside of Asia; companies will exchange broad licenses, subject to milestones and royalties, for in-house use of each other's technology for the development of antibody therapeutics; companies will initiate a research collaboration to create a novel approach for the development of fully human antibodies by combining their technologies; alliance could generate third-party milestones of more than $250M (1/00) |
MediGene AG (Germany) |
Aventis Pharma AG (unit of Aventis SA; NYSE:AVE) |
Research collaboration/Medigene's gene therapy tumor vaccine using recombinant adenoassociated viruses for treatment of malignant melanoma |
$34M |
Aventis gains an exclusive license to develop and commercialize the vaccine in 37 countries (including the European Union, North America and Japan) with rights to grant sublicenses; total deal value could amount to $34M, including up-front fees, milestones and R&D funding; in addition, MediGene will receive royalties on sales and promotion rights for most Eastern European countries and a number of South American, Far East and Middle East countries; Aventis will be responsible for manufacturing GMP material and will handle Phase III trials and regulatory matters (2/00) |
Millennium Pharmaceuticals Inc. (MLNM) |
Taisho Pharmaceutical Co. Ltd. (Japan) |
License agreement/Millennium's LDP-977 for the treatment of chronic asthma |
ND |
Companies signed a letter of intent granting Taisho an exclusive license in Japan, Asia and Europe; Taisho will fund all research and development expenses in Japan and Asia, and two-thirds of the expenses in the U.S. and Europe; Taisho also will pay a licensing fee, plus milestones based on progress in its territories; Millennium will manufacture the product for Taisho and receive supply fees based on sales; Taisho has the right of first negotiation for commercialization in the U.S. should Millennium seek to sublicense in that territory (1/00) |
Myriad Genetics Inc. (MYGN) |
Hoffmann-La Roche Inc. (Switzerland) |
Research collaboration/use of Myriad's ProNet to discover drug targets for treating heart disease |
$13 |
Myriad will receive up to $13M in research funding, license fees and milestones, plus royalties on any sales (1/00) |
Neurocrine Biosciences Inc. (NBIX) |
Taisho Pharmaceutical Co. Ltd. (Japan) |
Licensing option/Neurocrine's altered peptide ligand (NBI-6024) for diabetes |
$45 |
Taisho gains an exclusive option to license rights for Europe and Asia; approximate value of the collaboration is $45M, which includes licensing and option fees, milestones and reimbursement of 50% of worldwide development expenses; in addition, Neurocrine will receive royalties on sales in Taisho's territories (1/00) |
NeuroSearch A/S (Denmark; Copenhagen: NEUS.CO) |
Abbott Laboratories (NYSE:ABT) |
Research collaboration/use of NeuroSearch's drug discovery platform for a family of ion channels to discover compounds for treatment of a variety of central and peripheral nervous system disorders |
$17 |
Abbott gains exclusive worldwide rights to compounds discovered in the collaboration; Abbott will finance all R&D doneby both project partners, and will pay up to $17M in milestones for each successfully developed compound, as well as royalties on sales (1/00) |
Glaxo Wellcomeplc (UK; NYSE: GLX) |
Development agreement/NeuroSearch's antidepressant, NS2389 |
$57 |
NeuroSearch will receive a first-phase payment of $10M, additional premarketing milestones of up to $47M and royalties on any sales (1/00) |
|
Oceanix Biosciences Corp.* |
Glaxo Wellcome plc (UK; NYSE: GLX) |
Research collaboration and database access/Oceanix's Receptor Selectivity Mapping Database, which contains data on interactions between compounds and disease-related targets |
ND |
Glaxo gains non-exclusive access to the database for internal use in drug discovery and development; Glaxo will provide slected compounds to Oceanixto be screened against a range of molecular targets and included in the database and shared between Oceanix and Glaxo; agreement could encompass joint development of data mining tools; Glaxo will pay access and screening fees (2/00) |
OSI Pharmaceuticals Inc. (OSIP) |
R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ) |
License agreement/OSI's gene transcription patent estate |
ND |
OSI will receive annual fees, together with milestones and success payments from small-molecule gene transcription modulators developed and marketed; license is non-exclusive (1/00) |
American Home Products Corp. (NYSE:AHP) |
Cross-licensing agreement/OSI's gene transcription patent estate and a family of patents covering yeast screening technologies developed by AHP subsidiary American Cyanamid |
ND |
OSI gains access to American Cyanamid technology, including claims for recombinant expression of a variety of targets in yeast, including G protein-coupled receptors; cross-license allows American Cyanamid to retain exclusive rights to use the GPCR technologies in the agricultural field (1/00) |
|
Oxford BioMedica plc (LSE:OXB) |
AstraZeneca plc (UK;NYSE:AZN) |
Research collaboration/use of Oxford's LentiVector gene delivery technology to deliver genes that are central to a number of disease processes, including asthma |
ND |
ND (2/00) |
Oxford GlycoSciences plc (LSE:OGS) |
Bayer AG (Germany) |
Research collaboration/use of OGS' proteomicstechnology to identify disease-associated proteins as potential targets for drug discovery |
ND |
Bayer has committed funding for an initial term of two years and will pay milestones and royalties; parties will jointly own any intellectual property arising from collaboration, and OGS will have exclusive rights to commercialize diagnostic markers identified (3/00) |
Pharmacopeia Inc. (PCOP) |
NV Organon (The Netherlands) |
Research collaboration/small-molecule antagonists of interleukin-8 for treating inflammatory |
ND |
Pharmacopeia will receive research funding to pursue further chemical optimization of lead compounds already identified by Pharmacopeia; Organon will handle development and commercialization of lead compound (1/00) |
Phase-1 Molecular Toxicology Inc.* |
PE Biosystems Group (NYSE: PEB) |
Development collaboration/high-throughput gene expression assays for preclinical drug toxicity evaluations |
ND |
Phase-1 and PE will share technical responsibility for the development and validation of a panel of approximately 50 gene expression assays; Phase-1 will choose the target genes and validate the assays for the targets; PE will design, develop, manufacture and market the assays; Phase-1 also will develop positive controls (full-length cDNA clones) to test specificity of the assays; PE will market those controls; during the final stage of the project, Phase-1 will create a database of the gene expression profiles for the targeted genes for cDNA samples from rat and human cells exposed to 50 reference compounds; reagents for this panel will be made available in an ABI PRISM card format (3/00) |
Protein Design Labs Inc. (PDLI) |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
Research collaboration/use of PDL's humanization technology for an antibody to treat inflammatory and immunologically mediated diseases |
$1.5 |
Fujisawa will pay a $1.5M signing fee, plus milestones, annual maintenance fees and royalties on any product sales (2/00) |
Quantum Dot Corp.* |
Genomics Institute of the Novartis Research Foundation (unit of Novartis AG; Switzerland) |
Research collaboration/use of Quantum Dot's nanocrystals to develop biological assays for proteome analysis and gene expression |
ND |
ND (3/00) |
Quark Biotech Inc.* |
Shionogi & Co. (Japan) |
License agreement and research collaboration/use of Quark's technology to discover and analyze genes associated with osteoarthritis |
ND |
Quark will identify and characterize genes; Shionogi will develop and manufacture pharmaceutical and diagnostic candidates resulting from the genes and will have exclusive marketing rights in the Far East; companies will share marketing rights elsewhere (1/00) |
Sangamo BioSciences Inc.* |
Baxter Healthcare Corp. (U.S. subsidiary of Baxter International Inc.; NYSE:BAX) |
Research collaboration/development and commercialization of therapeutics for ischemic cardiovascular and peripheral vascular diseases using Sangamo's zinc finger DNA binding proteins (ZFPs) for activation of vascular endothelial growth factor |
$40 |
Sangamo may receive up to $40M in research funding, option fees, loans and milestones, and also will receive royalties on any sales; Sangamo will design and advance products through preclinical testing, and Baxter will be responsible for production, clinical trials, approvals and marketing; Baxter also gains a three-year right of first refusal to Sangamo's ZFP cardiovascular product candidates (1/00) |
Procter & Gamble Pharmaceuticals (unit of Procter & Gamble; NYSE: PG) |
Research collaboration/use of Sangamo's Universal GeneTools |
ND |
Sangamo will provide specific Universal GeneTools to P&G for internal research and validation (3/00) |
|
SkyePharma plc (SKYE) |
Pfizer Inc. (NYSE:PFE) |
Feasibility contract/use of SkyePharma's Geomatrix oral delivery technology to formulate a Pfizer compound |
ND |
ND (3/00) |
Synaptic Pharmaceutical Corp. (SNAP) |
Kissei Pharmaceutical Co. Ltd. (Japan) |
License agreement and research collaboration/identification and development of drugs that act through receptors which will be identified using Synaptic's genomics technologies |
ND |
Synaptic will receive a license fee, research funding, milestones and royalties on any drug that emerges from the program; Kissei will have worldwide exclusive rights to use selected receptors from the collaboration to develop, manufacture and market associated drugs (1/00) |
Synsorb Biotech Inc. (Canada; SYBB) |
BCY Ventures Inc. (CDNX: BCY) |
License agreement/Synsorb's technologies relating to treatment of complications associated with cystic |
ND |
BCY will issue up to 1.6M common shares to Synsorb, which will represent 30% of all shares of BCY on a fully diluted basis; BCY will issue 0.8M shares upon closing of the the transaction and an additional 0.8M shares upon achievement of milestones; Synsorb will act as a resource to BCY in developing the technologies (2/00) |
Titan Pharmaceuticals Inc. (AMEX:TTP) |
Schering AG (Germany) |
Development, manufacturing and commercialization agreement/Titan's cell therapy for the treatment of Parkinson's disease |
ND |
Titan and Schering will collaborate on the manufacturing and clinical development of product; Titan will receive funding for development activities, as well as reimbursement for some prior R&D expenses; Schering will fully fund, and manage in collaboration with Titan, all future clinical trials; Schering receives exclusive worldwide development, manufacturing and commercialization rights, and will pay royalties on any sales; Schering also has the right to make an equity investment in Titan upon initiation of pivotal clinical trials (2/00) |
Tripos Inc. (TRPS) |
Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA) |
Research collaboration/development of new informatics methods for high-throughput screening |
ND |
Three-year, multimillion dollar agreement under which Tripos and Parke-Davis will jointly design, develop and test screening analysis tools; results of the collaboration eventually will be made available as commercial software products (1/00) |
Vion Pharmaceuticals Inc. (VION) and EPTTCO Ltd.* (UK) |
AstraZeneca plc (UK; NYSE:AZN) |
Option agreement/anticancer therapies incorporating Vion's TAPET bacterial vector armed with EPTTCO's prodrug activation technology, which uses enzymes to convert inactive prodrugs into cytotoxics |
ND |
AstraZeneca will evaluate products over nine months; Vion and EPTTCO will handle preclinical testing and AstraZeneca will provide access under its rights to certain prodrugs; AstraZeneca has an exclusive option period to license the specific EPTTCO-armed TAPET vector; Vion and EPTTCO will receive option fees (1/00) |
Xenometrix Inc. (OTC BB:XENO) |
Pfizer Inc. (NYSE:PFE) |
License agreement/Xenometrix's Yeast DEL technology for measuring genotoxic potential of compouds |
ND |
Pfizer will incorporate Xenometrix's genotoxicology methods into its screening process (3/00) |
Notes: | ||||
# This chart contains information on new agreements, covering the time between 1/1/00 and 3/15/00. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 4/3/00 issue of BioWorld Financial Watch. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication). | ||||
Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 20-21. | ||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; NM = Nouveau Marche; OTC BB = Over The Counter Bulletin Board | ||||
ND = Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
